JP2023523016A5 - - Google Patents

Info

Publication number
JP2023523016A5
JP2023523016A5 JP2022564548A JP2022564548A JP2023523016A5 JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5 JP 2022564548 A JP2022564548 A JP 2022564548A JP 2022564548 A JP2022564548 A JP 2022564548A JP 2023523016 A5 JP2023523016 A5 JP 2023523016A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
domain
composition according
chimeric
substance according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022564548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023523016A (ja
JP7817948B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028775 external-priority patent/WO2021216956A1/en
Publication of JP2023523016A publication Critical patent/JP2023523016A/ja
Publication of JP2023523016A5 publication Critical patent/JP2023523016A5/ja
Application granted granted Critical
Publication of JP7817948B2 publication Critical patent/JP7817948B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022564548A 2020-04-23 2021-04-23 がんを処置するための組成物および方法 Active JP7817948B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014550P 2020-04-23 2020-04-23
US63/014,550 2020-04-23
PCT/US2021/028775 WO2021216956A1 (en) 2020-04-23 2021-04-23 Compositions and methods for treating cancer

Publications (3)

Publication Number Publication Date
JP2023523016A JP2023523016A (ja) 2023-06-01
JP2023523016A5 true JP2023523016A5 (cg-RX-API-DMAC7.html) 2024-04-26
JP7817948B2 JP7817948B2 (ja) 2026-02-19

Family

ID=78270118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022564548A Active JP7817948B2 (ja) 2020-04-23 2021-04-23 がんを処置するための組成物および方法

Country Status (12)

Country Link
US (1) US20230140868A1 (cg-RX-API-DMAC7.html)
EP (1) EP4110822A4 (cg-RX-API-DMAC7.html)
JP (1) JP7817948B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230019424A (cg-RX-API-DMAC7.html)
CN (1) CN115485301A (cg-RX-API-DMAC7.html)
AU (1) AU2021261003A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022019939A2 (cg-RX-API-DMAC7.html)
CA (1) CA3172092A1 (cg-RX-API-DMAC7.html)
IL (1) IL296576A (cg-RX-API-DMAC7.html)
MX (1) MX2022013207A (cg-RX-API-DMAC7.html)
PH (1) PH12022553129A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021216956A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102423686B1 (ko) * 2019-01-10 2022-07-21 에스지메디칼 주식회사 항 베타 1 인테그린 인간화 항체 및 이를 포함하는 암치료용 약학 조성물
US12319732B2 (en) 2019-01-10 2025-06-03 Sg Medical Inc. Anti-beta 1 integrin humanized antibody, and pharmaceutical composition for treating cancer, comprising same
WO2023056326A1 (en) * 2021-09-30 2023-04-06 Alpha Beta Holdings, Llc Compositions and methods for treating cancer
CN118542937A (zh) * 2023-02-24 2024-08-27 恒翼生物医药(上海)股份有限公司 抗αvβ3抗体和抗PD-1抗体的联合药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
JP2002508656A (ja) 1997-03-12 2002-03-19 スミスクライン・ビーチャム・コーポレイション 抗−アルファベータ3ヒト化モノクローナル抗体
US6160099A (en) 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
CA2436326C (en) * 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
AU2005277641A1 (en) 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
NO2699601T3 (cg-RX-API-DMAC7.html) * 2011-04-21 2018-06-16
LT2884999T (lt) * 2012-08-20 2021-04-12 Fred Hutchinson Cancer Research Center Ląstelinės imunoterapijos būdas ir kompozicijos
MX2015013163A (es) * 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
WO2015134988A1 (en) * 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
US20200109205A1 (en) * 2017-03-31 2020-04-09 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
BR112022001273A2 (pt) * 2019-08-02 2022-06-07 Univ California Composições e métodos para direcionar e matar células tronco cancerosas (cscs) positivas para alfa-v beta-3 (avss3) (cscs) e tratar cânceres metastáticos e resistentes a fármacos

Similar Documents

Publication Publication Date Title
CN108976300B (zh) Pd-1结合分子和其使用方法
JP2024009818A5 (cg-RX-API-DMAC7.html)
AU2017331256B2 (en) CD123 binding proteins and related compositions and methods
US11667712B2 (en) Materials and methods for modulating t cell mediated immunity
JP2019500014A5 (cg-RX-API-DMAC7.html)
JP2023541816A5 (cg-RX-API-DMAC7.html)
AU2022369278A1 (en) ANTI-EGFR ANTIBODIES, ANTI-cMET ANTIBODIES, ANTI-VEGF ANTIBODIES, MULTISPECIFIC ANTIBODIES, AND USES THEREOF
JP2023517660A5 (cg-RX-API-DMAC7.html)
JP2024524891A5 (cg-RX-API-DMAC7.html)
JP2021511298A5 (cg-RX-API-DMAC7.html)
US20240336686A1 (en) Novel multi-specific molecules
KR20230079390A (ko) 감소된 응집 능력 및 감소된 소수성을 갖는 개선된 항-oxMlF 항체
JP2025508075A5 (cg-RX-API-DMAC7.html)
WO2025201240A1 (en) Antibodies targeting cd3, cd28, and pd-l1 and uses thereof
US20220153869A1 (en) Shielded and homing bispecific antibody that simultaneously inhibits angiogenic pathway targets and her2 family proteins and uses thereof
WO2025245176A1 (en) Multispecific antibody constructs
EA052211B1 (ru) ВАРИАНТ Fc С ВЫСОКОЙ ТЕРМОСТАБИЛЬНОСТЬЮ И ОСЛАБЛЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JP2024508764A5 (cg-RX-API-DMAC7.html)
RU2023123926A (ru) Антитела к vista и их применение
NZ769634A (en) Anti-sirpa antibodies and methods of use thereof
NZ769634B2 (en) Anti-sirpa antibodies and methods of use thereof
NZ736674A (en) Anti-sortilin antibodies and methods of use thereof
NZ736674B2 (en) Anti-sortilin antibodies and methods of use thereof
HK40105492A (en) Lag-3-binding moleculkes and methods of use thereof